DiaSys Highlights Comprehensive Portfolio of New Assays at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023

Image: The HbA1c net FS uses a new enzymatic method for the determination of HbA1c (Photo courtesy of DiaSys)

DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is showcasing its new products, including its latest immunoturbidimetric test for the determination of procalcitonin, at Medlab Middle East 2023.

At this year’s Medlab Middle East, DiaSys is presenting its latest reagents HDL-c direct FS, LDL-c direct FS, Cystatin C FS, Procalcitonin FS and CRP FS. The company’s innovative new reagents, HDL-c direct FS and LDL-c direct FS, are homogenous assays for direct determination of high-density lipoproteins (HDL) and low-density lipoproteins (LDL). The high quality reagents offer long calibration and onboard stability of up to four months. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.

DiaSys is showcasing the Cystatin C FS, an immunturbidemetric assay that can be applied on a broad range of clinical chemistry analyzers. The assay is characterized by an outstanding analytical sensitivity in addition to superior correlation with nephelometry. It has excellent onboard and calibration stabilities up to 12 weeks and a high prozone security. The standardized test is essential for reliable kidney diagnosis of clinical-chemistry laboratories. DiaSys is also highlighting the Procalcitonin FS, a fluid-stable, particle enhanced immunoturbidimetric assay with outstanding onboard and calibration stability that provides a convenient workflow on clinical chemistry analyzers. Determinations of PCT in serum and plasma within the measuring range from 0.2 ng/mL to 50 ng/mL can be performed with high precision at clinical cut-off levels for sepsis. The performance is complemented by high tolerance to endogenous interferents and various therapeutics used in sepsis management. Procalcitonin FS shows a good correlation to established methods. Results from ring trials and a publication demonstrate the strengths of the assay.

In addition, DiaSys is highlighting the CRP FS liquid-stable immunoturbidimetric test with dedicated ready-to-use calibrators and controls. The test results are fully quantitative which allows true differentiation of borderline cases. The test is standardized to the international reference material, has a wide measuring range, high prozone security and excellent correlation to competitor tests. The test is easily applicable to clinical chemistry analyzers with a variety of instrument applications available.

Related Links:
DiaSys Diagnostic Systems